Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High – Time to Buy?

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $20.01 and last traded at $19.81, with a volume of 12391502 shares traded. The stock had previously closed at $16.51.

Wall Street Analyst Weigh In

Several equities analysts recently commented on TEVA shares. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.88.

Teva Pharmaceutical Industries Stock Up 1.5 %

The firm has a market cap of $24.02 billion, a PE ratio of -24.94, a PEG ratio of 0.99 and a beta of 0.79. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company’s 50-day simple moving average is $17.61 and its two-hundred day simple moving average is $17.45.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.55% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UMB Bank n.a. grew its stake in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the last quarter. Smithfield Trust Co grew its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $50,000. Claro Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $52,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at about $57,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.